Archer-Daniels-Midland Co vs Regeneron Pharmaceuticals Inc — how do they compare? Archer-Daniels-Midland Co trades at $80.75 (market cap $38.79B), while Regeneron Pharmaceuticals Inc trades at $796.39 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.1× Archer-Daniels-Midland Co's market cap, and Archer-Daniels-Midland Co pays the higher dividend (2.58%). Which is the better fit depends on your goals.
| ADM | REGN | |
|---|---|---|
Market Cap | $38.79B | $83.19B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $812.27 |
52-Week Low | $56.00 | $555.51 |
Enterprise Value | $47.04B | $77.90B |
Dividend Yield | 2.58% | 0.47% |
Signals from Pluang's Aura AI — not financial advice
ADM trades at $76.59, down 1.19% with a bearish technical signal despite recent earnings beats. The company raised its 2026 outlook after strong Q2 results driven by biofuels and crushing margins. Valuation appears reasonable with P/E of 20.93 and P/S of 0.45, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Analyst consensus is mixed with 33% buy ratings but a $88 price target suggesting 15% upside.
The stock offers value with solid dividends and improved cash flow, but faces execution risks and revenue pressure. Near-term catalysts include Q3 earnings and continued biofuels strength, while competitive pressures and margin compression remain concerns. The current price near support at $76 provides a potential entry point for long-term investors.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →